In July, the Centers for Disease Control and Prevention released preliminary statistics which show that last year drug overdose deaths increased significantly, reaching 93,000. The opioid epidemic seems to be getting worse with each passing day, which is why it’s surprising to learn that alcohol kills more individuals in America than drug overdoses do.
The National Institute on Alcohol Abuse and Alcoholism estimates that about 95,000 individuals succumb to alcohol-related causes every year.
Given that September was national recovery month, the time is ripe to evaluate and recognize the extent of the country’s alcohol dependence and highlight ways to help those suffering from alcohol use disorder.
A countrywide survey commissioned by the American Psychological Association at the start of the year found that one in every four adults drunk more in the past year as a way to manage stress. A separate study that was conducted by the not-for-profit research institute RTI International also found that between February and November 2020, the general alcohol consumption grew by almost 40%, with binge drinking also growing by 30% within the same time frame.
The study, which was funded by the National Institute on Alcohol Abuse and Alcoholism, also found that the highest increases in average consumption of alcohol were observed among women who had children aged five and below, Hispanic women, Black men and Black women. The percentage increases for these groups were found to be 323%, 148%, 173% and 173% respectively. Data from the National Institute on Alcohol Abuse and Alcoholism also shows that in 2019, more than 14 million individuals aged 18 and above suffered from alcohol use disorder.
Alcohol’s widespread availability and its accessibility makes it almost impossible to avoid. However, the clever marketing strategies of alcoholic beverage companies shouldn’t blind us to the fact that this beverage is no less dangerous than opioids such as fentanyl, it is just more socially acceptable and allowed.
Various resources exist that can help individuals with alcohol use disorder, most of which can be found with a simple online search. Examples include:
The attention of public health officials, the media and the public should remain focused on the opioid epidemic but should also include alcohol use disorder. By raising awareness, we will help save more lives from this preventable cause of death.
Many companies, including Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), are conducting research to develop effective remedies to deal with alcohol use disorder. These psychedelic-based medicines could flip the switch on the contemporary management of AUD.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The global market for brain tumor treatments is experiencing significant transformation powered by advances in…
A team of researchers has developed a “cost-effective” and simple blood test with the potential…
Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…
Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…
Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…
Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…